Key Highlights

  • On November 11, 2026, Oklo (NYSE:OKLO) reported that the US Department of Energy had signed off on the last operations hold point for the Groves Isotope Test Reactor, or Groves-1, in Lockhart, Texas.
  • With unrestricted operations now permitted for research, testing and training, the shares gained on the announcement as the wider market rallied.
  • Groves-1 achieved first criticality at low power in August 2026, under a year after groundbreaking, as part of the DOE Reactor Pilot Program.
  • Lessons from the reactor will go into Groves-2 Forge, a proposed isotope production pilot that begins with lutetium-177 for cancer therapy.

Why the DOE Decision Matters

The DOE ruling turns Groves-1 from a start-up project into an operating research and demonstration reactor for Oklo (NYSE:OKLO). Plans for the unit include Training staff, testing equipment such as control rod drive mechanisms and benchmarking criticality and reactivity data. This record carries weight because Oklo has no commercial power reactors in operation, so investors have priced the company mainly on future plans. Every regulatory step that moves a design toward a working Facility trims execution risk. Progress in 2026 has been swift: the safety analysis was approved on July 1, startup was authorised on July 23, first criticality was announced on August 6, and now unrestricted operations are cleared. The DOE Reactor Pilot Program was created to accelerate advanced reactor testing, and Groves-1 is one of the projects suggesting the pathway can take months instead of years. For a young company, showing that it can design, build and safely run a reactor is a credibility test with regulators, customers and investors.

A Second Business in Isotopes

The Texas site also supports another line of business. Oklo intends to apply what it learns there to Groves-2 Forge, a pilot to produce and process medical and industrial isotopes, beginning with lutetium-177. This isotope goes into targeted radiopharmaceuticals for prostate and neuroendocrine cancers, a segment expanding fast as big drugmakers grow their radioligand therapies. Medical isotope Supply has frequently been tight because it relies on a handful of ageing research reactors worldwide. Isotope sales could bring in Revenue sooner than the planned Aurora power plants, which need licensing and construction before they produce electricity. The site therefore acts as a bridge between current development spending and later commercial income, and it adds a healthcare customer base that depends less on the pace of data centre construction.

Hurdles and Indicators to Follow

Oklo is still pre-revenue, and its valuation rests on expectations that advanced nuclear power will serve data centres and industry. The main hurdles are Nuclear Regulatory Commission licensing of the commercial reactors, fuel supply for high-assay low-enriched uranium and construction costs. The shares have swung sharply with sentiment on AI power Demand and nuclear policy. Investors in Oklo (NYSE:OKLO), including those in Canada who reach US-listed names through a Canadian brokerage, will follow early operating data from Groves-1, progress on Groves-2 Forge, licensing steps for the first Aurora plant and customer agreements that turn interest into binding contracts. Spending will climb as projects advance, so funding needs and any new share sales also bear watching. Policy support for nuclear power in Washington is a tailwind, though political priorities can change.

Where Things Stand

The DOE has approved unrestricted research, testing and training at Oklo's Groves-1 test reactor in Texas, after first criticality in August 2026. The reactor offers operating experience and a foundation for a lutetium-177 isotope business. Commercial power plants are still years off, so licensing progress and customer contracts will keep driving the Investment case. This is one step on a long development path.